Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Galera Therapeutics (GRTX)
OTHER OTC:GRTX
Holding GRTX?
Track your performance easily
GRTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.05 - $0.29
Previous Close$0.08
Volume311.60K
Average Volume (3M)383.89K
Market Cap
$4.30M
Enterprise Value-$5.23M
Total Cash (Recent Filing)$10.75M
Total Debt (Recent Filing)$1.19M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Nov 12, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding54,392,170
10 Day Avg. Volume248,130
30 Day Avg. Volume383,892
Standard Deviation0.44
R-Squared0.05
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.03
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Galera Therapeutics News
PremiumCompany Announcements
Galera Therapeutics Announces Wind-Up and Special Stockholder Meeting
PremiumCompany Announcements
Galera Therapeutics Settles Clinical Trial Dispute Lawsuit
PremiumCompany Announcements
Galera Therapeutics Restructures Leadership and Cuts CostsOwnership Overview
38.86% Insiders
3.26% Mutual Funds
5.41% Other Institutional Investors
52.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GRTX FAQ
What was Galera Therapeutics’s price range in the past 12 months?
Galera Therapeutics lowest stock price was $0.05 and its highest was $0.29 in the past 12 months.
What is Galera Therapeutics’s market cap?
Currently, no data Available
When is Galera Therapeutics’s upcoming earnings report date?
Galera Therapeutics’s upcoming earnings report date is Nov 12, 2024 which is in 53 days.
How were Galera Therapeutics’s earnings last quarter?
Galera Therapeutics released its earnings results on Aug 14, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.07.
Is Galera Therapeutics overvalued?
According to Wall Street analysts Galera Therapeutics’s price is currently Overvalued.
Does Galera Therapeutics pay dividends?
Galera Therapeutics does not currently pay dividends.
What is Galera Therapeutics’s EPS estimate?
Galera Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galera Therapeutics have?
Galera Therapeutics has 54,392,170 shares outstanding.
What happened to Galera Therapeutics’s price movement after its last earnings report?
Galera Therapeutics reported an EPS of -$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 40%.
Which hedge fund is a major shareholder of Galera Therapeutics?
Among the largest hedge funds holding Galera Therapeutics’s share is Blackstone Inc.. It holds Galera Therapeutics’s shares valued at N/A.
---
Galera Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-66.06%
Trailing 12-Months
Company Description
Galera Therapeutics
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
---
GRTX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Adaptimmune Therapeutics
―
Karyopharm Therapeutics
―
Cellectar Biosciences
―
Fennec Pharmaceuticals
―
---